Biomarkers of therapeutic response with immune checkpoint inhibitors

Immune checkpoint inhibitors (ICPIs) have revolutionized the treatment paradigm of a wide range of malignancies with durable responses seen in even advanced, refractory cancers. Unfortunately, only a small proportion of patients with cancer derive meaningful benefit to ICPI therapy, and its use is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bindal, Poorva, Gray, Jhanelle E., Boyle, Theresa A., Florou, Vaia, Puri, Sonam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Cancer Immunotherapy: Recent Advances and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267267/
https://www.ncbi.nlm.nih.gov/pubmed/34277840
http://dx.doi.org/10.21037/atm-20-6396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267267/
https://www.ncbi.nlm.nih.gov/pubmed/34277840
http://dx.doi.org/10.21037/atm-20-6396

Ejemplares similares